Patents by Inventor Joseph Paul Marino, Jr.

Joseph Paul Marino, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • sEH inhibitors and their use
    Patent number: 7994317
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: August 9, 2011
    Assignee: GlaxoSmithKline, LLC
    Inventors: Yun Ding, Joseph Paul Marino, Jr., Peng Li, Allyn T. Londregan, Barry A. Morgan
  • Novel sEH Inhibitors and Their Use
    Publication number: 20100311775
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5, R6, R13, A, B, Y, Z, x, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: January 30, 2009
    Publication date: December 9, 2010
    Applicant: SmithKline Beecham Corporation
    Inventors: Joseph Paul Marino, JR., John Jeffrey McAtee
  • Novel sEH Inhibitors and their Use
    Publication number: 20100311776
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5a, R6a, A, B, K, L, M, Y, Z, l, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: January 30, 2009
    Publication date: December 9, 2010
    Inventors: Joseph Paul Marino, JR., John Jeffrey McAtee
  • NOVEL SEH INHIBITORS AND THEIR USE
    Publication number: 20100261743
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2a, R2b, Rya, R6a, A, B, K, L, M, Y, Z, l, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: December 4, 2008
    Publication date: October 14, 2010
    Inventors: Allyn T. Londregan, Joseph Paul Marino, JR., John Jeffrey McAtee
  • NOVEL sEH INHIBITORS AND THEIR USE
    Publication number: 20100210655
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R5a, R6a, A, B, Y, I, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: October 10, 2008
    Publication date: August 19, 2010
    Inventors: Yun Ding, Allyn T. Londregan, Joseph Paul Marino, JR.